WallStSmart

Bgin Blockchain Limited Class A Ordinary Shares (BGIN)vsZepp Health Corp (ZEPP)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Zepp Health Corp generates 26% more annual revenue ($258.90M vs $205.46M). ZEPP leads profitability with a -15.5% profit margin vs -28.2%. ZEPP earns a higher WallStSmart Score of 41/100 (D).

BGIN

Avoid

25

out of 100

Grade: F

Growth: 5.3Profit: 2.0Value: 6.7Quality: 7.3
Piotroski: 2/9Altman Z: 6.13

ZEPP

Hold

41

out of 100

Grade: D

Growth: 4.7Profit: 2.0Value: 6.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BGINUndervalued (+72.6%)

Margin of Safety

+72.6%

Fair Value

$10.50

Current Price

$3.37

$7.13 discount

UndervaluedFair: $10.50Overvalued
ZEPPUndervalued (+48.6%)

Margin of Safety

+48.6%

Fair Value

$46.70

Current Price

$17.47

$29.23 discount

UndervaluedFair: $46.70Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BGIN2 strengths · Avg: 9.0/10
Altman Z-ScoreHealth
6.1310/10

Safe zone — low bankruptcy risk

Price/BookValuation
2.5x8/10

Reasonable price relative to book value

ZEPP2 strengths · Avg: 10.0/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
43.0%10/10

Revenue surging 43.0% year-over-year

Areas to Watch

BGIN4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$360.90M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Return on EquityProfitability
-32.7%2/10

ROE of -32.7% — below average capital efficiency

ZEPP4 concerns · Avg: 2.0/10
Market CapQuality
$247.54M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-17.2%2/10

ROE of -17.2% — below average capital efficiency

EPS GrowthGrowth
-68.1%2/10

Earnings declined 68.1%

Profit MarginProfitability
-15.5%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : BGIN

The strongest argument for BGIN centers on Altman Z-Score, Price/Book.

Bull Case : ZEPP

The strongest argument for ZEPP centers on Price/Book, Revenue Growth. Revenue growth of 43.0% demonstrates continued momentum.

Bear Case : BGIN

The primary concerns for BGIN are EPS Growth, Market Cap, Piotroski F-Score.

Bear Case : ZEPP

The primary concerns for ZEPP are Market Cap, Return on Equity, EPS Growth.

Key Dynamics to Monitor

BGIN profiles as a turnaround stock while ZEPP is a hypergrowth play — different risk/reward profiles.

ZEPP is growing revenue faster at 43.0% — sustainability is the question.

Monitor COMPUTER HARDWARE industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ZEPP scores higher overall (41/100 vs 25/100) and 43.0% revenue growth. BGIN offers better value entry with a 72.6% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Bgin Blockchain Limited Class A Ordinary Shares

TECHNOLOGY · COMPUTER HARDWARE · USA

Bgin Blockchain Limited, is a digital asset technology company in Singapore, Hong Kong, the United States, and rest of Southeast Asia. The company is headquartered in Singapore.

Visit Website →

Zepp Health Corp

TECHNOLOGY · CONSUMER ELECTRONICS · China

Zepp Health Corporation, an activity and biometric data-driven company, develops, manufactures and sells smart wearable technology devices in the People's Republic of China. The company is headquartered in Hefei, the People's Republic of China.

Want to dig deeper into these stocks?